Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Otsuka
Pharma
Takeda, Lilly-Innovent, BIO-China—Fierce Pharma Asia
Takeda launched a restructuring. Innovent notched positive data for a GLP-1R/GCGR agonist. BIO warned of the harm from cutting off Chinese CDMOs.
Angus Liu
May 10, 2024 9:30am
Rexulti the surprise winner in April's TV drug ad spending list
May 7, 2024 9:40am
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
Apr 5, 2024 8:25am
Big Pharma deal spree, China plans and more—Fierce Pharma Asia
Jan 5, 2024 8:44am
Novartis-Legend, Astellas, Ajinomoto—Fierce Pharma Asia
Nov 17, 2023 8:00am
FDA rules key Otsuka marketing claim overstates Rexulti efficacy
Nov 13, 2023 8:05am